Dr Reddy’s Labs Q4 net profit plunges 86% | Hyderabad News
Hyderabad: Lower lenalidomide sales (Revlimid) in the North America markets dragged Dr Reddy’s Labs’ consolidated net profit by 86% for the fourth quarter ended March 31, 2026, to nearly Rs 221 crore as against Rs 1,587 crore in the corresponding quarter of last financial year. This was on a nearly 12% drop in consolidated revenues…
